Skip to main content
BioArctic logo

BioArctic — Investor Relations & Filings

Ticker · BIOA ISIN · SE0010323311 LEI · 549300Y0OI2WVUNHLC33 ST Professional, scientific and technical activities
Open in API
Filings indexed 432 across all filing types
Latest filing 2022-04-28 Interim / Quarterly Rep…
Country SE Sweden
Listing ST BIOA

About BioArctic

https://www.bioarctic.se/en/

BioArctic is a research-intensive biopharmaceutical company focused on developing disease-modifying treatments, biomarkers, and diagnostics for neurodegenerative diseases. The company's core strategy is based on its proprietary antibody technology, which develops unique treatments that target the misfolded and aggregated proteins considered to be the underlying cause of disorders such as Alzheimer's and Parkinson's disease. Through strategic partnerships with global pharmaceutical companies, BioArctic advances its innovative therapies from research through clinical development and commercialization, aiming to address significant unmet medical needs in neurology.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM REPORT January – March 2022' and contains comprehensive financial data, including a financial summary, key performance indicators, and detailed management commentary on operations and strategy. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2022
2022-04-28 English
AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
Legal Proceedings Report Classification · 1% confidence The document is a press release announcing that AbbVie has terminated its collaboration with BioArctic regarding a portfolio of alpha-synuclein antibodies. It details the history of the collaboration, the status of the lead asset (ABBV-0805), and includes quotes from the CEO. Crucially, the text ends with a statement: "This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on April 20, 2022..." This structure strongly suggests a mandatory regulatory disclosure regarding a significant corporate event (termination of a major partnership). Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific insider trade (DIRS), the most appropriate general category for a mandatory disclosure of this nature that doesn't fit other specific corporate action codes (like M&A/TAR or Financing/CAP) is the general regulatory filing category, RNS (Regulatory Filings). It is not an announcement of a report publication (RPA) but the announcement itself.
2022-04-20 English
AbbVie avslutar samarbetet med BioArctic kring alfa-synuklein-portföljen
M&A Activity Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) in Swedish and announces that AbbVie has decided to terminate its collaboration with BioArctic regarding the alpha-synuclein antibody portfolio, including ABBV-0805. It includes details about the termination, quotes from the CEO, and standard disclaimers regarding drug development. Crucially, it states: "Denna information är sådan information som BioArctic AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning." (This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU's Market Abuse Regulation.) This indicates a mandatory regulatory disclosure concerning a significant corporate event (termination of a major partnership). Since it is a general regulatory announcement that doesn't fit neatly into specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), the most appropriate classification is the general regulatory filing fallback category, RNS (Regulatory News Service/Announcements). The document length (4331 chars) is short enough that it is an announcement, not the full report itself.
2022-04-20 Swedish
Notice of Annual General Meeting in BioArctic AB (Publ)
AGM Information Classification · 1% confidence The document explicitly states, 'The Board of BioArctic AB has resolved to convene an Annual General Meeting of shareholders to be held on Thursday, 5 May 2022' and is titled 'NOTICE OF ANNUAL GENERAL MEETING IN BIOARCTIC AB (PUBL)'. The content details the procedures for advance voting, the proposed agenda items (including election of directors, approval of remuneration, and allocation of results), which are all characteristic features of a notice for an Annual General Meeting (AGM). This directly corresponds to the AGM Information category.
2022-04-06 English
Kallelse till årsstämma i BioArctic AB (publ)
AGM Information Classification · 1% confidence The document is titled "KALLELSE TILL ÅRSSTÄMMA I BIOARCTIC AB (PUBL)" which translates to "NOTICE OF ANNUAL GENERAL MEETING IN BIOARCTIC AB (PUBL)". It details the date (May 5, 2022), the procedure for voting (advance voting due to Covid-19), and presents a detailed agenda ("Förslag till dagordning") covering items typical for an AGM, such as election of the chairman, approval of financial statements, discharge of directors, determination of board fees, election of directors, and proposals regarding remuneration reports and authorization for new share issues. The content is explicitly about convening and setting the agenda for the Annual General Meeting (Årsstämma). This directly corresponds to the AGM Information category.
2022-04-06 Swedish
Annual Report (ESEF) 2021
Annual Report (ESEF) Classification · 1% confidence FY 2021
2022-03-31 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.